Cargando…
Treatment of MDA5-positive dermatomyositis complicated by gangrenous cholecystitis with tofacitinib
BACKGROUND: Dermatomyositis is a rare idiopathic inflammatory disease with diverse presentations that can have varying degrees of cutaneous and systemic involvement. This phenotypic heterogeneity makes DM a therapeutic challenge. Some therapeutic drugs, such as hormones and immunosuppressants, have...
Autores principales: | Luo, Man, Chen, Long, He, Huan, He, Fang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9107581/ https://www.ncbi.nlm.nih.gov/pubmed/35570320 http://dx.doi.org/10.1186/s40001-022-00693-0 |
Ejemplares similares
-
Efficacy and safety of dose escalation of tofacitinib in refractory anti-MDA5 antibody-positive dermatomyositis
por: Ida, Tomoaki, et al.
Publicado: (2023) -
Case report: Successful treatment of anti‐MDA5‐positive to negative dermatomyositis‐associated interstitial lung disease with the JAK inhibitor tofacitinib
por: Jiang, Zong, et al.
Publicado: (2023) -
Editorial: Anti-MDA5-Positive Dermatomyositis
por: Gono, Takahisa, et al.
Publicado: (2022) -
Clinical Features of Dermatomyositis/Polymyositis with Anti-MDA5 Antibody Positivity
por: Chen, Qiuhe, et al.
Publicado: (2022) -
Anti-MDA5 antibody-positive dermatomyositis presenting as unilateral eyelid edema
por: Chen, Lauren, et al.
Publicado: (2020)